Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor α receptor IgG1-Fc fusion complex therapy

Journal of the American Academy of Dermatology

Volumn 45, Issue 6, 2001, Pages 953-956

  Smith, Kathleen J ^a   Skelton, Henry G ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; TUMOR GROWTH;

EID: 0035179804     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.117725     Document Type: Article

References (20)

1. Biologic agents and immunotherapy in rheumatoid arthritis
2. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
3. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
4. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other disease
5. Update on treatment of rheumatoid arthritis
6. Biological insights from clinical trials with anti-TNF therapy
7. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
8. Anticytokine therapy: A new era in the treatment of rheumatoid arthritis?
9. H2-mediated responses
10. Signal transduction through NF-κβ
11. Cytokines
12. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: Complex regulation by IL-4, IL-10 and CD40L
13. H1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12
14. Bypassing the antigen to control rheumatoid arthritis
15. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis
16. H2 cells?
17. Transplantation of human malignant and premalignant skin lesions of epidermis to nude mice
18. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
19. Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises
20. Tumor necrosis factors in 1998